Anti-seizure medication
PreclinicalSmall molecule
Anti-seizure medication is one of 26 small molecule programs targeting Status Epilepticus. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
41 competitors in Status Epilepticus
#DrugCompanyPhaseTrials
1Keppra
UCBApproved
Ketalar
AAultman Health Foundation
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Epidiolex
Jazz PharmaceuticalsApproved
Depakote
AbbViePhase 3
Vimpat
UCBPhase 3
Actemra
RochePhase 3
Luminal
BBiomed Industries, Inc.
Phase 3
Ativan
BBausch Health Americas, Inc.
Phase 3
Fintepla
IImmedica Pharma AB
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anti-seizure medication. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMayo Clinic